PMID- 34640520
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211016
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 10
IP  - 19
DP  - 2021 Sep 29
TI  - Prevalence, Incidence and Associates of Pulmonary Hypertension Complicating Type 
      2 Diabetes: Insights from the Fremantle Diabetes Study Phase 2 and National 
      Echocardiographic Database of Australia.
LID - 10.3390/jcm10194503 [doi]
LID - 4503
AB  - There is a paucity of epidemiologic data examining the relationship between 
      pulmonary hypertension (PH) and diabetes. The aim of this study was to determine 
      prevalence, incidence and associates of PH complicating type 2 diabetes. Data 
      from 1430 participants (mean age 65.5 years, 51.5% males) in the Fremantle 
      Diabetes Study Phase 2 (FDS2) were linked with the National Echocardiographic 
      Database of Australia (NEDA) to ascertain the prevalence and incidence of PH 
      (estimated right ventricular systolic pressure (eRVSP) >30 mmHg as a new 
      suggested threshold or the conventional >40 mmHg) over a 12-year period. PH 
      prevalence in FDS2 was compared with that in NEDA overall and a geographically 
      close sub-population. Multivariable analyses identified associates of 
      prevalent/incident PH in the FDS2 cohort. Of 275 FDS2 patients (19.2%) with 
      pre-entry echocardiography, 90 had eRVSP >30 mmHg and 35 had eRVSP >40 mmHg 
      (prevalences 32.7% (95% CI 27.3-38.7%) and 12.7% (9.1-17.4%), respectively), 
      rates that are 35-50% greater than national/local NEDA general population 
      estimates. Moreover, 70 (5.0%) and 123 (9.2%) FDS2 participants were identified 
      with incident PH at the respective eRVSP thresholds (incidence (95% CI) 7.6 
      (6.0-9.7) and 14.2 (11.8-17.0)/1000 person-years), paralleling data from 
      recognised high-risk conditions such as systemic sclerosis. The baseline plasma 
      N-terminal pro-brain natriuretic peptide concentration was the strongest 
      independent associate of prevalent/incident PH. Approximately 1 in 8 people with 
      type 2 diabetes have PH using the eRVSP >40 mmHg threshold. Its presence should 
      be considered as part of regular clinical assessment of individuals with type 2 
      diabetes.
FAU - Nundlall, Nishant
AU  - Nundlall N
AD  - School of Medicine, The University of Notre Dame, Fremantle, WA 6160, Australia.
FAU - Playford, David
AU  - Playford D
AD  - School of Medicine, The University of Notre Dame, Fremantle, WA 6160, Australia.
FAU - Strange, Geoff
AU  - Strange G
AD  - School of Medicine, The University of Notre Dame, Fremantle, WA 6160, Australia.
AD  - The Heart Research Institute, Newtown, NSW 2042, Australia.
AD  - Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, 
      Australia.
AD  - Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, 
      Sydney, NSW 2006, Australia.
FAU - Davis, Timothy M E
AU  - Davis TME
AUID- ORCID: 0000-0003-0749-7411
AD  - Fremantle Hospital, Medical School, The University of Western Australia, 
      Fremantle, WA 6160, Australia.
FAU - Davis, Wendy A
AU  - Davis WA
AUID- ORCID: 0000-0002-5709-8235
AD  - Fremantle Hospital, Medical School, The University of Western Australia, 
      Fremantle, WA 6160, Australia.
LA  - eng
GR  - 513781/National Health and Medical Research Council/
GR  - APP1042231/National Health and Medical Research Council/
GR  - APP1126886/National Health and Medical Research Council/
GR  - N/A/Spinnaker Health Research Fund/
PT  - Journal Article
DEP - 20210929
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC8509549
OTO - NOTNLM
OT  - incidence
OT  - prevalence
OT  - pulmonary hypertension
OT  - risk factors
OT  - type 2 diabetes
COIS- The authors declare no conflict of interest.
EDAT- 2021/10/14 06:00
MHDA- 2021/10/14 06:01
PMCR- 2021/09/29
CRDT- 2021/10/13 01:11
PHST- 2021/08/31 00:00 [received]
PHST- 2021/09/25 00:00 [revised]
PHST- 2021/09/27 00:00 [accepted]
PHST- 2021/10/13 01:11 [entrez]
PHST- 2021/10/14 06:00 [pubmed]
PHST- 2021/10/14 06:01 [medline]
PHST- 2021/09/29 00:00 [pmc-release]
AID - jcm10194503 [pii]
AID - jcm-10-04503 [pii]
AID - 10.3390/jcm10194503 [doi]
PST - epublish
SO  - J Clin Med. 2021 Sep 29;10(19):4503. doi: 10.3390/jcm10194503.